MedTrace Logo

Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients

NCT06034353 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 385

Last updated 2025-01-31

No results posted yet for this study

Summary

The purpose of this interventional study is to assess the impact of pharmacist-led cognitive behavioral intervention in epileptic patients. The main questions are:

1. If pharmacist-led cognitive behavioral therapy can help in improving patient medication adherence?
2. How will the cognitive behavioral therapy impact the quality of life of the patients?

Participants of this study will be provided basic or advanced level counselling and educational material as part of their routine pharmacy visit.

Researchers will compare the two groups (Basic and advanced) to see which of the two groups are better in term of medication adherence and quality of life.

Conditions

Interventions

BEHAVIORAL

Pharmacist-led Cognitive Behavioral therapy

Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.

Sponsors & Collaborators

  • Hamdard University

    lead OTHER

Principal Investigators

  • Matti Ullah, PhD · Hamdard University Islamabad Campus

  • Iqra Farooq, MPhil · Shifa International Hospital

  • Muhammad Shafiq, BS. (Hons.) · Subhan Medical Trust

  • Emmama Jamil, MPhil · Hamdard University Islamabad Campus

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-22
Primary Completion
2024-05-20
Completion
2024-07-15

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06034353 on ClinicalTrials.gov